Each year diabetes researchers from all over the world gather for the annual meeting of the Advanced Technologies & Treatments for Diabetes (ATTD), which this year will take place on February 19-22 in Madrid, Spain. Many of the latest advances will be discussed, including research that Breakthrough T1D has funded to advance new breakthroughs and therapies for people with type 1 diabetes (T1D). In total, 28 researchers presenting are Breakthrough T1D-funded, either now or in the past, and four members of the Breakthrough T1D team will be in attendance.
Here are highlights of Breakthrough T1D-funded research that will be featured at the ATTD conference:
- Open-Protocol Automated Insulin Delivery A discussion by Breakthrough T1D Director of Research, Dan Finan, Ph.D., along with Jessie Wong, Ph.D., who will talk about the psychosocial considerations of the artificial pancreas technology on people with T1D, and Courtney Lias, Ph.D., who will lay out the FDA’s vision for open-protocol systems
- Latest Artificial Pancreas Systems, including an on-body artificial pancreas technology in children (Francis Doyle, Ph.D., and Eyal Dassau, Ph.D., Harvard University, Roman Hovorka, Ph.D., University of Cambridge, and Boris Kovatchev, Ph.D., University of Virginia)
- Screening. General population screening for T1D, moderated by Breakthrough T1D Senior Director of Research, Jessica Dunne, Ph.D., and featuring Marian Rewers, M.D., Ph.D., from the University of Colorado
- Adjunct Therapies. The drug, methyldopa (used to treat high blood pressure), in new-onset T1D (Peter Gottlieb, M.D., University of Colorado) and the use of SGLT inhibitors (Chantal Mathieu, M.D., Ph.D., KU Leuven, and Thomas Danne, M.D., Hannover Medical School)
- Pregnancy. Artificial pancreas systems in pregnancy (Helen Murphy, FRACP, M.D., Kings College London)
- Exercise. Technical challenges of exercise management in T1D (Michael Riddell, Ph.D., York University)
Stay tuned on Twitter (@JDRFResearch) for exciting news at the ATTD Conference!
